Helena Florindo

Group Leader at Research Institute for Medicines, University of Lisbon | Helena Florindo graduated in Pharmaceutical Sciences in 2003 (University of Lisbon) and obtained her Ph.D. degree in Pharmaceutical Technology in 2008 (University of Lisbon), in collaboration with the University of London. Currently, she is an Associate Professor with tenure and habilitation in the department of Pharmacy, Pharmacology and Health Technologies at the Faculty of Pharmacy, University of Lisbon. Since 2015, she is the head of the BioNanoSciences – Drug Delivery & Immunoengineering Research Group, at the Research Institute for Medicines (iMed.ULisboa), University of Lisbon. Helena is also a member of the Portuguese Medicines Agency Evaluation Board (INFARMED) and an expert to the European Medicines Agency (EMA), thus supporting the evaluation of marketing authorization procedures for new drugs and biologics. This knowledge in regulatory sciences also guides the research within her research group, which has been motivated by the immune-oncology field towards the rational development of functionalized nanobiomaterials as novel immunotherapies for cancer treatment. It includes the characterization of the anti-tumor effects induced by the combination of nano-vaccines with nano-therapeutics designed to modulate the functions of key cells within tumor microenvironment, such as T cells, myeloid-derived cells and tumor cells.